
    
      This randomized controlled trial will enroll 132 patients with postherpetic neuralgia. All
      patients will be randomly assigned to either the EA combined with medication group or the
      medication group via a computerized central randomization system in a 1:1 ratio. Primary
      outcomes will be change in sensory thresholds and pain intensity. Secondary outcomes will be
      change in dosage of analgetic, quality of life, anxiety and depression severity and sleep
      quality.
    
  